Summary by Futu AI
Transcode Therapeutics, Inc. has filed an amendment to its definitive proxy statement with the SEC to correct an error regarding the quorum requirement for its upcoming Annual Meeting of Stockholders. The amendment clarifies that a quorum will require one-third of the outstanding shares entitled to vote, either present in person or represented by proxy. This correction aligns with the company's Amended and Restated Bylaws and the Delaware General Corporation Law. The Annual Meeting is scheduled for June 13, 2024, at Goodwin Procter LLP's offices in Boston, MA. The amendment does not change any other information in the original proxy statement, and stockholders who have already submitted their proxy cards or voting instructions do not need to take further action unless they decide to change their vote.